Moving on past sola wreckage, Lilly doubles down on one more Alzheimer’s drug from AstraZeneca
Eli Lilly may be down today as a result of the final readout of the numbers on solanezumab. But it’s not out.
The pharma giant …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
